title: Anti-IgE treatment: an update.
authors.affiliation: Medical Specialties, Mail Point 810, Southampton General Hospital, Southampton SO16 6YD, UK.
authors.forename: K S
authors.initials: KS
authors.lastname: Babu
authors.forename: S H
authors.initials: SH
authors.lastname: Arshad
authors.forename: S T
authors.initials: ST
authors.lastname: Holgate
mesh_terms: D000293:Adolescent; D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy; D002648:Child; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D000069444:Omalizumab; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E